Tag : Checkpoint

Biology

Snail synchronizes endocycling in a TOR-dependent manner to coordinate entry and escape from endoreplication pausing during the <i>Drosophila</i> critical weight checkpoint

Newsemia
by Jie Zeng, Nhan Huynh, Brian Phelps, Kirst King-Jones The final body size of any given individual underlies both genetic and environmental constraints. Both mammals...
Cardiology

Cardiovascular complications of anti-cancer immune checkpoint inhibitor therapy and their combinations: are we ready for challenges ahead?

Newsemia
The use of immune checkpoint inhibitors (ICIs) has transformed the treatment landscape for a number of tumour types over the past decade. Targeting cytotoxic T-lymphocyte-associated...
Biology

A kinase-dependent checkpoint prevents escape of immature ribosomes into the translating pool

Newsemia
by Melissa D. Parker, Jason C. Collins, Boguslawa Korona, Homa Ghalei, Katrin Karbstein Premature release of nascent ribosomes into the translating pool must be prevented...
Biology

Delineating the contribution of Spc105-bound PP1 to spindle checkpoint silencing and kinetochore microtubule attachment regulation

Newsemia
Accurate chromosome segregation during cell division requires the spindle assembly checkpoint (SAC), which detects unattached kinetochores, and an error correction mechanism that destabilizes incorrect kinetochore–microtubule...
Latest News

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management

Newsemia
Shivaji, UN; Jeffery, L; Gui, X; Smith, SCL; Ahmad, OF; Akbar, A; Ghosh, S; Shivaji, UN; Jeffery, L; Gui, X; Smith, SCL; Ahmad, OF; Akbar,...
Pharma / Biotech

A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.

Newsemia
Related Articles A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib...
Latest News

Scientists discover novel mechanism of action for NK cells in checkpoint inhibitor for cancer

Newsemia
PD-L1 checkpoint inhibitors are a powerful and growing form of immunotherapy used to treat melanoma, kidney cancer, head and neck cancers, Hodgkin’s lymphoma and other...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy